Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis.

van der Togt, Céleste J T; Ten Cate, David F; van den Bemt, Bart J F; Rahamat-Langendoen, Janette; den Broeder, Nathan; den Broeder, Alfons A

van der Togt, Céleste J T; Ten Cate, David F; van den Bemt, Bart J F; Rahamat-Langendoen, Janette; den Broeder, Nathan; den Broeder, Alfons A.

Afiliação

van der Togt CJT; Department of Rheumatology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Ten Cate DF; Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands.
van den Bemt BJF; Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands.
Rahamat-Langendoen J; Department of Pharmacy, Sint Maartenskliniek, Ubbergen, The Netherlands.
den Broeder N; Department of Clinical Pharmacy, Radboudumc, Nijmegen, The Netherlands.
den Broeder AA; Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.

Rheumatology (Oxford) ; 62(4): 1627-1630, 2023 04 03.

Article em En | MEDLINE | ID: mdl-36000861

Assuntos

Antirreumáticos; Artrite Reumatoide; COVID-19; Humanos; Rituximab/uso terapêutico; Vacinas contra COVID-19/uso terapêutico; Antirreumáticos/uso terapêutico; Soroconversão; COVID-19/prevenção & controle

Palavras-chave

COVID-19; RA; biologic therapies; rituximab; vaccination

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / COVID-19 Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google